JOP20170135A1 - مركبات ديازاسبيروألكيل مثيل-إندول - Google Patents

مركبات ديازاسبيروألكيل مثيل-إندول

Info

Publication number
JOP20170135A1
JOP20170135A1 JOJO/P/2017/0135A JOP20170135A JOP20170135A1 JO P20170135 A1 JOP20170135 A1 JO P20170135A1 JO P20170135 A JOP20170135 A JO P20170135A JO P20170135 A1 JOP20170135 A1 JO P20170135A1
Authority
JO
Jordan
Prior art keywords
compounds
diazaspiroalkylmethyl
preparation
pharmaceutical formulations
indoles
Prior art date
Application number
JOJO/P/2017/0135A
Other languages
English (en)
Inventor
Ter Laak Antonius
Siegel Stephan
Haendler Bernard
STRESEMANN Carlo
Ernesto Fernandez-Montalvan Amaury
Stockigt Detlef
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of JOP20170135A1 publication Critical patent/JOP20170135A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

يتعلق الاختراع الحالي بمركبات diazaspiroalkylmethyl-indole بالصيغة العامة (I): (I) حيث يكون R8، X و Y كمت عرف هنا، وطريق لتحضير المركبات المذكورة، ومركبات وسيطة مفيدة لتحضير المركبات المذكورة، وتراكيب صيدلية وتوليفات تشمل المركبات المذكورة واستخدام المركبات المذكورة لتصنيع تراكيب صيدلية للمعالجة أو الوقاية من الأمراض، تحديدا السرطان، في صور عامل لوحده أو في توليفة مع مكونات فعالة اخرى.
JOJO/P/2017/0135A 2016-05-31 2017-05-30 مركبات ديازاسبيروألكيل مثيل-إندول JOP20170135A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16172216 2016-05-31
EP16205809 2016-12-21

Publications (1)

Publication Number Publication Date
JOP20170135A1 true JOP20170135A1 (ar) 2017-11-30

Family

ID=58745252

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2017/0135A JOP20170135A1 (ar) 2016-05-31 2017-05-30 مركبات ديازاسبيروألكيل مثيل-إندول

Country Status (2)

Country Link
JO (1) JOP20170135A1 (ar)
WO (1) WO2017207387A1 (ar)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE49687E1 (en) 2014-09-09 2023-10-10 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
WO2016197027A1 (en) 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
WO2017161028A1 (en) 2016-03-16 2017-09-21 Kura Oncology, Inc. Substituted inhibitors of menin-mll and methods of use
US10752639B2 (en) 2016-03-16 2020-08-25 Kura Oncology, Inc. Bridged bicyclic inhibitors of menin-MLL and methods of use
US12084462B2 (en) * 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
AU2017326487B2 (en) * 2016-09-14 2021-08-05 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
TWI753016B (zh) 2016-09-14 2022-01-21 比利時商健生藥品公司 Menin-mll相互作用之稠合二環抑制劑
KR102513564B1 (ko) 2016-12-15 2023-03-22 얀센 파마슈티카 엔.브이. 메닌-mll 상호작용의 아제판 억제제
CN110691779B (zh) 2017-03-24 2023-10-10 库拉肿瘤学公司 治疗血液系统恶性肿瘤和尤因肉瘤的方法
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
TW201920170A (zh) 2017-09-20 2019-06-01 美商庫拉腫瘤技術股份有限公司 經取代之menin-mll 抑制劑及使用方法
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
JP7307729B2 (ja) * 2017-12-20 2023-07-12 ヤンセン ファーマシューティカ エヌ．ベー． メニン－ｍｌｌ相互作用のエキソ－アザスピロ阻害剤
CN112105621B (zh) 2018-03-30 2024-02-20 住友制药株式会社 光学活性桥型环状仲胺衍生物
US12662494B2 (en) * 2018-08-08 2026-06-23 Sumitomo Pharma Co., Ltd. Optically active bridged piperidine derivative
US12703680B2 (en) 2019-11-21 2026-08-11 University Of Utah Research Foundation TRPV4 receptor ligands
UY38988A (es) 2019-12-19 2021-06-30 Janssen Pharmaceutica Nv Derivados espiráncos sustituidos de cadena lineal
CN114478568A (zh) * 2020-10-27 2022-05-13 苏州优理生物医药科技有限公司 一种噻吩并嘧啶类化合物、包含其药物组合物及其应用
EP4334310A1 (en) 2021-05-08 2024-03-13 JANSSEN Pharmaceutica NV Substituted spiro derivatives
BR112023021040A2 (pt) * 2021-05-08 2024-02-06 Janssen Pharmaceutica Nv Derivados espiro substituídos
CA3218479A1 (en) 2021-06-01 2022-12-08 Wei Cai Substituted phenyl-1h-pyrrolo[2, 3-c]pyridine derivatives
WO2022253289A1 (en) 2021-06-03 2022-12-08 Janssen Pharmaceutica Nv Pyridazines or 1,2,4-triazines substituted by spirocyclic amines
AU2022292697A1 (en) 2021-06-17 2024-02-01 Janssen Pharmaceutica Nv (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer
AU2023323878A1 (en) * 2022-08-11 2025-01-30 Remynd N.V. (aza)spiroheptane derivatives for the treatment of neurodegenerative disorders
US20260151399A1 (en) 2022-11-24 2026-06-04 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer
AR132185A1 (es) 2023-03-24 2025-06-04 Acerta Pharma Bv COMPUESTOS DE 1-H-PIRROLO[2,3-c]PIRIDINA

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999065494A1 (en) 1998-06-15 1999-12-23 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
WO2005047286A1 (ja) 2003-11-13 2005-05-26 Ono Pharmaceutical Co., Ltd. スピロ複素環化合物
MXPA06013250A (es) 2004-05-14 2007-02-28 Abbott Lab Inhibidores de quinasa como agentes terapeuticos.
JP2010503675A (ja) 2006-09-15 2010-02-04 シェーリング コーポレイション 疼痛、糖尿病および脂質代謝の障害の治療に有用なスピロ縮合アゼチジン誘導体
US20080070888A1 (en) 2006-09-15 2008-03-20 Mckittrick Brian A Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism
AU2010289321A1 (en) 2009-09-04 2012-04-05 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
AU2014249233A1 (en) 2013-03-13 2015-09-24 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
US9212180B2 (en) 2013-06-12 2015-12-15 The Regents Of The University Of Michigan Menin-MLL inhibitors and methods of use thereof
WO2014200479A1 (en) 2013-06-12 2014-12-18 The Regents Of The University Of Michigan Menin-mll inhibitors and methods of use thereof
US20170119769A1 (en) 2014-06-10 2017-05-04 The Trustees Of The University Of Pennsylvania Scaffolds for inhibitors of menin-mll interactions
WO2016197027A1 (en) 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物

Also Published As

Publication number Publication date
WO2017207387A1 (en) 2017-12-07

Similar Documents

Publication Publication Date Title
JOP20230073A1 (ar) بنزاميدات مستبدلة مع 3،1- ثيازول-2- يل
ECSP19030002A (es) 1,2,4-triazolonas 2,4,5-trisustituidas
DOP2019000117A (es) Nuevos derivados de quinolina
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
MX389697B (es) Nuevos derivados de pirazolopirimidina.
CO2020001244A2 (es) Derivados de quinolina para tratar infecciones con helmintos
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
PH12020500134A1 (en) Dihydrooxadiazinones
PH12015502539B1 (en) Cenicriviroc compositions and methods of making and using the same
PH12015500713A1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
UA113538C2 (xx) Фторметил-5,6-дигідро-4h-$1,3]оксазини
EA201690687A1 (ru) Ингибиторы репликации вируса иммунодефицита
EA201591541A1 (ru) Ингибиторы бета-секретазы 1 (bace 1)
DOP2016000253A (es) Nuevos compuestos
EA201591406A1 (ru) C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
TR201900148T4 (tr) Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin.
MX2015007540A (es) Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1).
PH12017501133A1 (en) Pyrazolopyridinamines
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
CY1120602T1 (el) [1,2,4]τριαζολο[4,3-β]πυριδαζινες για χρηση στη θεραπευτικη αντιμετωπιση πολλαπλασιαστικων ασθενειων
EA201792264A1 (ru) Способы лечения воспалительных заболеваний
JOP20170127A1 (ar) صيغة مشتركة مكونة من ثلاث مركبات مضادة للفيروسات